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Abstract
 
Primary biliary cirrhosis (PBC) is characterized by an intense biliary inflammatory CD4
 
 
 
 and
CD8
 
 
 
 T cell response. Very limited information on autoantigen-specific cytotoxic T lympho-
cyte (CTL) responses is available compared with autoreactive CD4
 
 
 
 T cell responses. Using
peripheral blood mononuclear cells (PBMCs) from PBC, we identified an HLA-A2–restricted
CTL epitope of the E2 component of pyruvate dehydrogenase (PDC-E2), the immunodomi-
nant mitochondrial autoantigen. This peptide, amino acids 159–167 of PDC-E2, induces spe-
cific MHC class I–restricted CD8
 
 
 
 CTL lines from 10/12 HLA-A2
 
 
 
 PBC patients, but not
controls, after in vitro stimulation with antigen-pulsed dendritic cells (DCs). PDC-E2–specific
CTLs could also be generated by pulsing DCs with full-length recombinant PDC-E2 protein.
Furthermore, using soluble PDC-E2 complexed with either PDC-E2–specific human mono-
clonal antibody or affinity-purified autoantibodies against PDC-E2, the generation of PDC-
E2–specific CTLs, occurred at 100-fold and 10-fold less concentration, respectively, com-
pared with soluble antigen alone. Collectively, these data demonstrate that autoantibody,
helper, and CTL epitopes all contain a shared peptide sequence. The finding that autoantigen–
immune complexes can not only cross-present but also that presentation of the autoantigen is
of a higher relative efficiency, for the first time defines a unique role for autoantibodies in the
pathogenesis of an autoimmune disease.
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Introduction
 
While a large body of data has accumulated on the precise
identification of the autoAgs that serve as targets for hu-
moral immune responses and significant data exists on the
nature of the autoAg-specific CD4
 
 
 
 Th cell responses in
primary biliary cirrhosis (PBC)
 
*
 
, information on the nature
of autoAg-specific CTL responses is relatively unknown (1,
2). Characterization of the CD8
 
 
 
 CTL response in PBC is
important as such cells are likely involved in the lysis of bil-
iary epithelial cells (BECs), the major target involved in the
pathogenesis of this disease. Identification of the autoAg
peptide, that is the target of MHC class I–restricted CTLs
in PBC, will provide an important initial step not only in
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BCL, Epstein-Barr virus-transformed B
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determining the mechanism by which tolerance to the self-
peptide is abrogated, but also in facilitating the potential for
therapeutic strategies.
Several sequence patterns or motifs for peptides that bind
to particular MHC molecules or groups of MHC molecules
have been defined by analysis of peptides presented by MHC
class I molecules (3, 4). Amongst the best-studied motif is
that of the MHC class I HLA-A2 molecule which is preva-
lent in 50% of the Caucasian population in the Western
Hemisphere (5, 6). In fact, motif prediction analysis of HLA-
A2 has led to the identification of the dominant epitopes of
the human myelin basic proteins (7) and glutamic acid de-
carboxylase (8), the key autoAgs in multiple sclerosis and in-
sulin-dependent diabetes mellitus, respectively.
Our present efforts focused on determining whether an
HLA-A2–restricted CTL epitope of the E2 component of
pyruvate dehydrogenase (PDC-E2), the immunodominant
autoAg of PBC, could be identified. We report herein the
successful use of this predictive approach to identify
epitopes for autoreactive CTLs in PBC. Specifically, pep-
tide epitopes, identified by scanning the PDC-E2 se-
quences for the presence of potential HLA-A2–binding
motifs, were synthesized and tested in vitro for their ability
to induce HLA-A2–restricted peptide-specific responses. In
addition to the traditional cytotoxicity assay for CTLs, we
also used a single-cell based intracellular cytokine staining
assay (9) in efforts to better characterize the autoreactive
CTLs. Using this strategy, we identified one HLA-A2–
restricted peptide, amino acids 159–167 of PDC-E2,
which is capable of inducing PDC-E2–specific CD8
 
 
 
 CTL
lines in vitro in the majority of HLA-A2
 
 
 
 PBC patients but
not from any HLA-A2
 
 
 
 control donors.
We also hypothesized that PDC-E2–specific autoAbs,
detected exclusively in PBC patients, may capture PDC-E2
Ags released from dying cells to form PDC-E2 immune
complexes (ICs), which may facilitate the uptake of PDC-
E2 Ag through Fc
 
 
 
 receptors (Fc
 
 
 
Rs) on professional
APCs. The fact that HLA-A2–expressing APCs when incu-
bated with the recombinant PDC-E2 (rPDC-E2) protein
could lead to the generation of CD8
 
 
 
 CTL specific for the
PDC-E2 peptide in association with the HLA-A2 molecule
suggests that such a peptide is in fact naturally processed
from exogenous Ag and then presented. Of interest also
was the finding that when APCs were loaded with PDC-
E2-ICs, not only was a PDC-E2 peptide-specific CD8
 
 
 
CTL line induced, but the efficiency of generating specific
CD8
 
 
 
 CTL lines was 100-fold more efficient based on the
net molar concentration of the immunodominant PDC-E2
peptide required. Our findings thus support the thesis that
autoAbs can facilitate the priming of CD8
 
 
 
 T cell responses
against soluble autoAg and that cross-priming may play an
important role in the induction of autoimmune response in
PBC with autoAb playing a contributory key role.
 
Materials and Methods
 
Patients.
 
12 HLA-A2
 
 
 
 patients with PBC and eight control
patients were studied. Controls included four HLA-A2
 
 
 
 patients
 
with other chronic liver diseases (two alcoholic hepatitis, one
granulomatous hepatitis, and one 
 
 
 
-antitrypsin deficiency) and
four HLA-A2
 
 
 
 healthy individuals. The HLA-A2 haplotype of
the subjects was determined by using A2-specific mAbs MA2.1
and BB7.2 (10). In addition, PBMCs from non-HLA-A2 pa-
tients were also collected for subsequent use as a source of con-
trol target cells.
 
Cells.
 
PBMCs from each subject were purified from venous
blood using standard Ficoll-Histopaque gradient centrifugation
techniques. The isolated cells were either used immediately or
cryopreserved for later use. Epstein-Barr virus-transformed B
lymphoblastoid cell lines (BCLs) were established from each do-
nor and maintained in RPMI 1640 (GIBCO BRL) supplemented
with 10% heat-inactivated FCS, penicillin (50 u/ml), and strepto-
mycin (50 
 
 
 
g/ml; FCS medium).
 
Synthetic Peptides and Recombinant Protein.
 
A panel of 12 pep-
tides derived from the amino acid sequence of PDC-E2 (11) were
selected using the software of the Bioinformatics and Molecular
Analysis Section (developed by K. Parker, National Institutes of
Health, Washington, D.C.), which ranks 9-mer peptides based
on a predicted half-time dissociation coefficient for HLA class I
molecules (12). A previously defined HLA-A2–restricted CTL
epitope, amino acids 18–27 of the Hepatitis B virus core protein
(HBc), was used as a negative control (5). All peptides were syn-
thesized with a free NH
 
2
 
 and a free COOH terminus, and their
purity confirmed by HPLC. Lyophilized peptides were reconsti-
tuted at 10 mg/ml in DMSO and diluted in FCS medium before
use. pET-PDC-E2 encoding PDC-E2 amino acids 1–561 was
constructed by inserting the corresponding gene into pET vector
(Promega). rPDC-E2 was expressed in 
 
Escherichia coli
 
 BL21 (In-
vitrogen) transformed with pET-PDC-E2 and purified.
 
Generation of Peptide-induced CTL Lines.
 
Immature dendritic
cells (DCs) were generated from PBMCs of HLA-A2 positive
donors as described previously (13) and used as APCs. In brief,
PBMCs were resuspended in FCS medium, seeded in a 250-ml
culture flask, and incubated at 37
 
 
 
C for 1.5 h. After removing
nonadherent cells in the medium, the adherent cells were fed
with FCS medium supplemented with GM-CSF (1,000 U/ml;
Peprotech) and IL-4 (1,000 U/ml; Peprotech) and cultured at
37
 
 
 
C. On day 7, cells were harvested and incubated overnight in
FCS medium containing either a mixture of the 12 peptides (10
 
 
 
M of each peptide) or a single peptide (10 
 
 
 
M). The cells were
then washed and 
 
 
 
-irradiated (5,000 rad). Cryopreserved PBMCs
were thawed, washed twice with HBSS, resuspended in FCS
medium, and seeded in 24-well plates at 2
 
   
 
10
 
6
 
 cells per well
along with 2
 
   
 
10
 
5
 
 peptide-pulsed APCs. Cells were cultured at
37
 
 
 
C for a total of 12–14 d with appropriate feeding of the cul-
tures with media as required. On day 3 recombinant human IL-2
(Peprotech) was added to each well at a final concentration of 10
U/ml.
 
Generation of CTL Lines by Exogenous Ags and ICs.
 
A PDC-
E2–specific human mAb was harvested from the culture superna-
tant of a specific cell line, purified by affinity chromatography,
and concentrated (14). An isotype-matched phosphatidyl-serine
specific control human mAb was prepared in the same way. L-
 
 
 
-Phos-
phatidyl-L-serine was purchased from Sigma-Aldrich. Soluble ICs
of rPDC-E2 and the human mAb was prepared by mixing rPDC-
E2 with affinity purified PDC-E2–specific Ab at a molar ratio of
1:2 for 1 h. Phosphatidyl-serine ICs were prepared in the same
way and used throughout as a control. To prepare F(ab)
 
 
 
2
 
 frag-
ment of the anti–PDC-E2 human mAb, a PDC-E2–specific hu-
man mAb was treated with pepsin and F(ab)
 
 
 
2 
 
fragment were fur-
ther purified. In addition, sera from PBC patients were affinity 
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purified against rPDC-E2 as described previously (15). In parallel,
control Abs were purified from normal sera. APCs were incu-
bated with soluble rPDC-E2 alone or rPDC-E2 mixed with ei-
ther mAb, F(ab)
 
 
 
2
 
 fragment of mAb, or Abs purified from sera at
different concentrations for 48 h, 
 
 
 
-irradiated, washed, and incu-
bated with PBMCs to induce specific CTLs as described above.
 
Intracellular Cytokine Analysis Using Flow Cytometry.
 
Uncul-
tured PBMCs or peptide-induced CTL lines were incubated in
fresh FCS medium with peptide (10 
 
 
 
M) and brefeldin A (10
 
 
 
g/ml; Sigma-Aldrich) for 4 h at 37
 
 
 
C. Cells were harvested and
treated first with FACS
 
® 
 
lysing solution and then with FACS
 
®
 
permeabilizing solution (BD Biosciences). The processed cells
were resuspended in 50 
 
 
 
l of FACS
 
® 
 
buffer (0.5% BSA and
0.05% sodium azide in PBS) and stained with PE-labeled anti-
CD8 (Caltag), TC-labeled anti-CD4 (Caltag), and FITC-labeled
Abs against one of the following cytokines: IFN-
 
 
 
; TNF-
 
 
 
; or
IL-2 (BD Biosciences). After incubation at room temperature in
the dark for 30 min, the cells were washed twice with FACS
 
®
 
buffer, fixed with 1% paraformaldehyde in PBS, and analyzed on
a FACScan™ flow cytometer. The acquired data were analyzed
with CELLQuest™ software (BD Biosciences).
 
Analysis of Costimulatory Molecule Expression on Immature
DCs.
 
Immature DCs were prepared for use as APCs as above.
The cells were incubated with either PDC-E2 ICs or control
phosphatidyl serine ICs for 48 h as described previously. Thence
the cells were harvested, resuspended in 50 
 
 
 
l of FACS
 
® 
 
buffer,
and stained with FITC-labeled anti-CD11c, CD40, or CD80 and
PE-labeled anti-CD1a, CD11c, or CD86 together with a cocktail
of TC-labeled anti-CD3, CD14, CD19, and CD56 (Caltag or
BD Bioscience). After incubation in the dark for 30 min at room
temperature, the cells were washed twice with FACS
 
® 
 
buffer,
fixed with 1% paraformaldehyde in PBS, and analyzed on a FAC-
Scan™ flow cytometer. The acquired data were analyzed with
CELLQuest™.
 
Vaccinia Vector.
 
VVrPDC-E2, a recombinant vaccinia virus
expressing amino acids 1–414 of the PDC-E2 protein, was con-
structed as described by inserting the corresponding coding se-
quence into the plasmid pMJ601 (16). Stocks of the recombinant
virus were prepared. Wild-type vaccinia virus prepared similarly
was used as a negative control.
 
Cytotoxicity Assay.
 
Autologous BCLs were used as target
cells. The cells were pulsed with peptides (10 
 
 
 
M) at 37
 
 
 
C over-
night. Alternatively, the BCLs were infected with VVrPDC-E2
or wild-type vaccinia virus at a multiplicity of infectivity of 10:1
at room temperature for 1 h, washed once, incubated overnight
at 37
 
 
 
C, washed, and then used as target cells. To assess the Ag-
specific cytolytic activity of the CTL lines, a fluorescence-based
cytotoxicity assay was performed with DELFIA europium (Eu)
2,2
 
 
 
:6
 
 
 
,2
 
  
 
–terpyridine–6,6
 
  
 
–dicarboxylic acid (TDA) cytotoxic-
ity assay reagents (Wallac). In brief, the previously prepared Ag-
pulsed target cells were washed, labeled with TDA, washed again,
and resuspended in FCS medium; 5 
 
 
 
 10
 
3
 
 target cells in a vol-
ume of 0.1 ml were plated into each well of 96-well round bot-
tomed plates, followed by the addition of varying numbers of ef-
fector cells in 0.1 ml of medium. After a 4-h incubation at 37
 
 
 
C,
the plates were centrifugated and a 20-
 
 
 
l portion of the superna-
tant from each well was collected and dispensed into a separate
96-well microtiter plate which contained 200 
 
 
 
l of DELFIA Eu
solution in each well. The Eu forms a stable complex with re-
leased TDA in the mixture and generates fluorescence. The fluo-
rescence of EuTDA was measured by a time-resolved fluorome-
ter (1420 VECTOR; Wallac Oy). Percentage cytotoxicity was
calculated by the formula: 100 
 
  
 
(release in assay 
 
 
 
 spontaneous
 
release)/(maximum release 
 
 
 
 spontaneous release). Maximum
release was determined by the lysis of 5 
 
 
 
 10
 
3
 
 labeled target cells
in triplicate wells with DELFIA lysis buffer (Wallac Oy). Sponta-
neous release was measured by incubating 5
 
  
 
 10
 
3
 
 target cells in
triplicate wells in the absence of effector cells. In all instances,
spontaneous release was 
 
 
 
15% of maximum release. Results are
reported herein as the mean of triplicate values.
 
Phenotypic Analysis of the CTL Line.
 
In efforts to confirm that
the CTL activity being measured was a function of CD8
 
 
 
 T cells,
effector cells generated as described above were incubated with
either CD4 or CD8 mAb-coated magnetic Dynabeads (Dynal).
The cells bound to the beads were removed and the depleted cell
population was assessed in triplicate for cytotoxicity against ap-
propriate peptide-pulsed autologous target cells. An aliquot of the
CD4- or CD8-depleted cells were analyzed for viability and for
the purity of depletion. Viability was always 
 
 
 
80% and the de-
pletion 
 
 
 
95%.
 
Inhibition of CTL Activity by Abs.
 
For determination of inhi-
bition, a mAb against HLA class I (W6/32), HLA class II DR
(TAL.1B5; Dako), or a control mAb (mouse IgG2; Caltag) was
added respectively to the peptide-loaded target cells at a predeter-
mined optimally titered dilution and incubated for 30 min at 4
 
 
 
C.
After incubation, the target cells were mixed with effector cells
for the EuTDA release assay.
 
Statistical Analysis.
 
Values were statistically analyzed using the
Fisher’s exact test.
 
Results
 
Identification of an Autoreactive CTL Epitope on PDC-
E2.
 
Potential HLA-A2–restricted CTL epitopes en-
coded by PDC-E2 were determined by scanning the
amino acid sequence of the PDC-E2 protein for the pres-
ence of 9-mer peptides containing the HLA-A2–binding
motif. This analysis resulted in the identification of 12
sequences that showed motifs similar to known CTL
epitopes and these are shown in Table 1. PBMCs from four
HLA-A2
 
 
 
 PBC patients were cocultured with autologous
APCs pulsed with a mixture of all 12 peptides for 12 d to
expand peptide-specific CD8
 
 
 
 T cells in vitro. After incu-
bation, the cells were divided into aliquots and restimulated
with individual peptides in the presence of brefeldin A, fol-
lowed by intracellular staining for IFN-
 
 
 
. Only one of the
12 candidate peptides, PD5, induced a significant fre-
quency of IFN- –producing T cells after in vitro culture of
PBMCs derived from each of the four patients (data not
shown). Flow cytometric analysis demonstrated that all of
the IFN- –producing cells expressed CD8. These results
suggest that PD5-specific CD8  T cells exist in the PBMC
cultures after stimulation with the peptide pool. Of interest
was the finding that the PD5 peptide spans residues amino
acids 159–167 of PDC-E2, which is located within the in-
ner lipoyl domain of PDC-E2.
PDC-E2 Peptide (159–167)-specific CD8  CTL T Cells:
Disease and Peptide Specificity. In an effort to examine the
disease specificity of the CD8  T cells against the identified
PDC-E2 epitope (159–167) peptide, PBMCs from all 20
HLA-A2  donors (12 PBC patients, PBC 1 to PBC 12;
four patients with other chronic liver diseases CL1 to CL4,
and four healthy donors H1 to H4) were cultured with au-116 CD8  Cells in PBC
tologous APCs loaded with the PD5 peptide. On day 12
the cells were restimulated with PD5 or a control peptide
in the presence of brefeldin A, followed by intracellular
IFN-  staining. A significant number of IFN- –producing
cells were detected after restimulation with PD5, but not
with the control peptide, in 10 out of 12 (83%) PBC pa-
tients but none of the eight control individuals (P   
0.0007). Representative data from two PBC patients
(PBC3 and PBC10) and two control individuals (CL1 and
H1) are shown in Fig. 1 A, and the results of all 20 individ-
uals tested are summarized in Fig. 1 B. The fact that PD5-
specific CD8  T cells can be expanded from the majority
Table I. Computer Algorithm Predicted HLA-A2–restricted Epitopes on PDC-E2
Figure 1. PD5-specific CD8  T cells from in vitro–cultured PBMCs. PBMCs from HLA-A2  do-
nors were cocultured with PD5-loaded APCs (autologous immature DCs) for 12 d, then restimulated
with PD5 or a control peptide in the presence of brefeldin A, followed by intracellular staining for
IFN- . (A) IFN-  staining of samples from two PBC patients, PBC3 and PBC10, and two control do-
nors, CL1 (alcoholic liver disease) and H1 (a healthy donor). Displayed in the dot plots are cells gated
for lymphocyte population by forward-scattering and side-scattering and the CD4  population. The
cells within the box are considered IFN-  . The number next to the box is the percentage of IFN-  
cells in the CD8  T cell population. (B) Frequency of PD5-specific CD8  T cells in PD5-stimulated
PBMC cultures derived from all 20 donors. The cut off value for a positive response was determined as
0.150%, or 3 SD above the mean percentage of IFN-  producing cells in all 20 samples restimulated
with the control peptide. A significant number of IFN- –producing cells were detected after restimu-
lation with PD5 in 10/12 (83%) PBC patients but in 0/8 control individuals (P   0.0007).117 Kita et al.
(10/12) of PBC patients but none of the control individuals
strongly suggests that a CD8  T cell response against the
autoreactive epitope on PDC-E2 is associated with PBC.
To determine if the IFN-  synthesizing CD8  T cell re-
sponse corresponded with PD5 peptide specific cytotoxic
activity, the PD5-stimulated PBMC cultures were assessed
in 14 HLA-A2  individuals: eight patients with PBC
(PBC1, PBC2, PBC3, PBC4, PBC5, PBC9, PBC10, and
PBC11); three patients with other chronic liver diseases
(CL1, CL2, and CL3); and three healthy controls (H1, H2,
and H3). The PBMCs were stimulated and expanded with
PD5-loaded autologous APCs for 12–14 d and used as ef-
fector cells in a conventional CTL assay against autologous
BCLs loaded with the PD5 peptide or a control HLA-A2–
specific hepatitis B peptide. Targets loaded with PD5, but
not with the control peptide, were lysed by the effector
cells derived from each of the eight PBC patients. In con-
trast, PBMCs derived from the control individuals did not
show significant cytotoxicity toward the PD5-loaded target
cells. A representative CTL assay for two PBC patients
(PBC9 and PBC11) is shown in Fig. 2 A along with two
control individuals (CL2 and H2) in Fig. 2 B. These results
indicate that PD5-specific CTL lines, inducible from PBC
patients but not from other chronic liver diseases or healthy
individuals, were indeed cytolytic for the targets presenting
the PD5 epitope.
To examine whether the PD5 epitope is in fact naturally
processed, presented, and serves as a target for the autore-
active CTLs, PD5 peptide-specific CTL lines from six
PBC patients (PBC1, PBC2, PBC3, PBC4, PBC5, and
PBC11) were tested for CTL activity using autologous
BCL targets infected with VVrPDC-E2, a vaccinia vector
carrying the coding sequence for 74% of the NH2 terminus
of the PDC-E2 gene. Wild-type vaccinia virus-infected
target cells were used as a control. PD5-induced CTL lines
from all six patients lysed target cells infected with VVr-
PDC-E2 as well as BCLs loaded with PD5 peptide as ex-
pected, but did not lyse, to any appreciable extent, targets
infected with the wild-type vaccinia virus or target cells
loaded with the control peptide. Representative data from
a PBC patient (PBC1) are shown in Fig. 2 C. These find-
ings indicate that the endogenously synthesized PDC-E2
protein is processed to generate the PD5 peptide, which is
presented and recognized by the peptide PD5-induced
CTL lines from PBC patients.
The CD8  phenotype of PD5-induced CTLs from six
PBC patients (PBC2, PBC3, PBC4, PB5, PBC10, and
PBC11) was also confirmed by a cytotoxicity assay after
depletion of different T cell subsets. Depletion of the
CD4 or CD8 fraction was performed after the in vitro
priming and expansion of the CTLs and before the cyto-
toxic assay. In all patients tested, the CTL activity was ab-
rogated by depletion of CD8  cells, but not by depletion
of CD4  cells, consistent with the view that CTL activity
was mediated by CD8  T cells, which likely synthesize
IFN-  when restimulated with the specific peptide. Rep-
Figure 2. Cytotoxicity of PD5-induced CTL lines. PD5-
specific CTL lines, induced by culturing PBMCs with
PD5-loaded APCs for 12–14 d, were tested for their cyto-
toxicity against PD5 or control peptide-loaded autologous
BCL targets at different effector/target (E/T) ratios.
HBc18–27, an HLA-A2-restricted irrelevant epitope, was
used as control. Displayed are mean specific lysis of triplicate
cultures. (A) PBC patients PBC9 and PBC11. (B) Control
donors CL2 (granulomatous liver disease) and H2 (healthy
donor). (C) Cytotoxic activity of a PD5-induced CTL line
against target cells presenting endogenously processed
PDC-E2 Ag. The CTL line from patient PBC1 was tested
for cytotoxicity against autologous BCL targets infected
with a PDC-E2–expressing vaccinia vector (VVrPDC-E2),
wild-type vaccinia virus (VVwild) alone, loaded with PD5
or a control peptide HBc18–27. Displayed are mean specific
lysis of triplicate testing at an E/T ratio of 40:1. (D) Pheno-
type analysis of PD5-induced CTLs. CD4  cell or CD8 
cells were depleted respectively from a CTL line derived
from patient PBC2 using anti-CD4 or anti-CD8–coated
magnetic beads before testing for cytotoxic activity with
PD5 or control peptide-loaded autologous BCL targets.
Unfractionated cells were also tested in parallel. Specific cy-
totoxicity was calculated by subtracting the cytotoxicity of
the effector cells against control peptide-pulsed BCLs from
that against PD5 peptide-pulsed BCLs. Displayed are mean
specific lysis of triplicate testing at an E/T ratio of 40:1
according to the cell counts before depletion.118 CD8  Cells in PBC
resentative data from a PBC patient (PBC2) are shown in
Fig. 3 D.
HLA Restriction of the PD5 Epitope. In efforts to con-
firm that class I restriction is involved in the presentation of
the PD5 peptide to CD8  CTLs, the cytotoxic activity of
PD5-specific CTL lines from four patients were tested in
the presence of Abs against class I or II HLA molecules.
The CTL activity was inhibited by anti-HLA class I Ab but
not by anti-HLA class II (DR) Ab in all cases tested. Rep-
resentative data from a PBC patient (PBC5) are shown in
Fig. 3 A. Then we examined the ability of CTL lines de-
rived from PBC patients to lyse PD5-loaded allogeneic
BCLs derived from five individuals, each with a distinct
combination of MHC class I haplotypes. Three PBC pa-
tients (PBC4, PBC9, and PBC11), all positive for HLA-
A2, were tested. As shown in Fig. 3 B, the presence of the
HLA-A2 allele alone is sufficient for a specific BCL line to
be lysed by all three CTL lines. Collectively, these results
confirm that the epitope PD5 was restricted by the MHC
class I–encoded HLA-A2 molecule.
Cytokine Profile of the PD5-specific CD8  T Cells. PD5-
specific CTL lines derived from four PBC patients (PBC9,
PBC10, PBC11, and PBC12) were restimulated with PD5
or control peptide in the presence of brefeldin A, followed
by intracellular staining for the cytokines IFN- , TNF- ,
and IL-2. Significant numbers of IFN- –producing CD8 
cells were detected in all four patients. However, no de-
tectable level of cells producing TNF-  or IL-2 was ob-
served in any of the patients studied (data not shown). The
failure to detect TNF-  and IL-2 was not secondary to ki-
netics (data not shown).
Generation of Autoreactive CTLs using Exogenous Ag and
Ag–Ab Complexes. To determine if exogenous PDC-E2
protein can induce CTL lines specific for the MHC class
I–restricted epitope PD5, PBMCs from three PBC patients
(PBC9, PBC10, and PBC11) were cocultured with APCs
loaded with rPDC-E2 protein or the PD5 peptide at vari-
ous concentrations. CTL assays were performed against au-
tologous BCLs targets loaded with either the PD5 peptide
or a control peptide. CTL lines with PD5-specific cytotox-
icity were consistently generated from each of the three
PBC patients when PBMCs were stimulated with APCs
loaded with PD5 peptide at concentrations   0.1   M.
However, when rPDC-E2 protein was used instead, PD5-
specific CTL lines could only be generated when the
PDC-E2 protein was added at the highest concentration
(10  M). Representative results of patient PBC10 is shown
in Fig. 4 A. These data suggest that APCs exogenously
pulsed with the soluble PDC-E2 protein, can still process
and present the peptide by the MHC-class I molecule but
at a relatively inefficient level.
To examine whether the internalization and presentation
of exogenous protein Ag can be enhanced by formation of
Ag–Ab complexes, experiments were performed using sol-
uble rPDC-E2 protein complexed with either a human
mAb against PDC-E2, a control mAb, or control ICs, then
added to the APCs at various concentrations. When the
anti–PDC-E2 mAb was added to form the Ag–Ab com-
plex with rPDC-E2 protein, PD5-specific CTL lines were
generated at 100-fold lower concentration than rPDC-E2
mixed with the control mAbs as well as control ICs, indi-
cating the internalization and presentation of exogenous
PDC-E2 protein was greatly enhanced by the formation of
specific Ag–Ab complex. Representative results with pa-
tient PBC10 are shown in Fig. 4 B. The highly efficient
PDC-E2 presentation was not due to Fc R engagement
per se, since induction of CTL activity with the soluble
rPDC-E2 was not enhanced by the presence of the irrele-
vant mAb as well as irrelevant ICs. The level of expression
of select costimulatory molecules, including CD40, CD80,
and CD86 by APCs incubated with the ICs were also ex-
amined in efforts to determine whether increased expres-
sion could be responsible for the enhanced generation of
CTLs. APCs were thus incubated with PDC-E2 ICs or
Figure 3. (A) Inhibition of CTL activity by HLA class I
and HLA class II (DR) mAbs. A CTL line derived from
patient PBC5 was tested for cytotoxicity against PD5 or
control peptide-loaded autologous BCL targets in the
presence of predetermined optimal concentrations of Abs
against different HLA molecules. Ab against HLA class I
(W6/32), HLA class II DR (TAL.1B5; Dako) or a control
Ab (mouse IgG2a; Caltag) were added respectively to the
peptide-loaded targets and incubated for 30 min at 4 C.
After the incubation the target cells were mixed with effec-
tor cells for EuTDA release assay. The CTL assays were
performed at an E/T ratio of 40:1. Specific cytotoxicity was
calculated by subtracting the cytotoxicity of the effector
cells against control peptide-pulsed BCLs from that
against PD5 peptide-pulsed BCLs. Displayed are mean
specific lysis of triplicate testing. (B) HLA restriction of
the PD5 epitope. CTL lines derived from three PBC pa-
tients were tested for cytotoxicity against PD5 or control
peptide-loaded allogeneic BCLs derived from five indi-
viduals with distinct combinations of HLA haplotypes.
The CTL assays were performed at an E/T ratio of 40:1.
Specific cytotoxicity was calculated by subtracting the cytotoxicity of the effector cells against control peptide-pulsed BCLs from that against PD5 pep-
tide-pulsed BCLs. Displayed are mean specific lysis of triplicate testing.119 Kita et al.
with control phosphatidyl serine ICs for the same period of
time as used for pulsing of the APCs with Ag. Results of
such studies failed to demonstrate any significant changes
of the level of expression in those molecules between con-
trol ICs or PDC-E2 ICs and between pre- and post-ICs in-
cubation. While these data do not completely rule out a
role for the contribution of such costimulatory molecules
and/or additional costimulatory molecules not studied, at
face value the data do not support such a role.
Next, to assess the effect of Ag aggregation on the inter-
nalization and presentation of exogenous protein Ag, ex-
periments were performed using soluble rPDC-E2 protein
alone or soluble rPDC-E2 complexed with an F(ab) 2 frag-
ment of anti–PDC-E2 human mAb, added to the APCs at
serial concentrations. When the F(ab) 2 fragment of anti–
PDC-E2 mAb was added with rPDC-E2 protein, the con-
centration required to induce PD5-specific CTL lines was
similar to that of rPDC-E2 alone, suggesting that increased
cross-presentation of ICs was not due to Ag aggregation.
Representative results with patient PBC9 are shown in
Fig. 4 B.
Generation of Autoreactive CTLs Using Exogenous Ag Mixed
with AutoAbs Purified from PBC Sera. PDC-E2–specific
autoAbs are detected exclusively in PBC patients. To ex-
amine whether the efficient internalization and presenta-
tion of exogenous PDC-E2 could be mediated with auto-
Abs in PBC sera, experiments were performed using
soluble rPDC-E2 protein complexed with affinity purified
autoAbs from PBC sera. When the autoAbs from PBC was
added to form the Ag–Ab complex with rPDC-E2 protein,
PD5-specific CTL lines were generated at 10-fold lower
concentration than rPDC-E2 mixed with Abs from control
sera, indicating that autoAbs in PBC have a potential to en-
hance internalization and presentation of exogenous PDC-
E2 protein by the formation of specific Ag–Ab complex.
Representative results with patient PBC11 are shown in
Fig. 4 C.
Discussion
In disease states which involve tissue destruction and im-
mune-mediated cell lysis, the identification and character-
ization of autoreactive T lymphocyte responses, and the
nature of the peptide and the MHC encoded restricting el-
ement, is an important step in defining the role of these
cells in disease pathogenesis. Previous work has focused on
the characterization of CD4  T cell lines and CD4  T cell
clones specific for PDC-E2 (17, 18). However, little work
has been performed to define the CD8  CTL response in
PBC. Immunohistochemical studies reveal that the portal
infiltrates in PBC are predominantly CD3  T cells contain-
ing both CD8  and CD4  subsets bearing the 2 -TCR.
The CD4/CD8 ratio ranges from 2–2.5:1 (19, 20). CD8 
T cells are most abundant during early stages of disease and
as the disease progresses, a higher proportion of CD4  T
cells are observed (21, 22). In this paper, we identified PD5
as an HLA-A2–restricted epitope on PDC-E2, the major
target protein of autoreactive Ab in PBC. PD5 peptide is
capable of inducing peptide-specific CTL lines after 12–14 d
of in vitro stimulation with PBMCs from the majority
(83%) of PBC patients but not from control patients, sug-
gesting that the PD5-specific CTLs are primed in vivo in
PBC patients. The PD5-specific CTL lines generated from
the patients’ PBMCs display CTL effector function, in-
cluding Ag-specific cytolytic activity and IFN-  produc-
tion. Therefore, it is reasonable to assume that the autoAg-
Figure 4. Induction of PD5-specific CTL lines with peptide, exogenous rPDC-E2 protein, or rPDC-E2 complexed with specific Abs. The cytotoxic-
ity of CTL lines generated with the different Ags was tested against autologous BCL targets loaded with PD5 or control peptide at an E/T ratio of 40. (A)
PBMCs from patient PBC10 were cocultured for 12 d with APCs loaded with rPDC-E2 protein or PD5 peptide at serial concentrations as indicated. (B)
PBMCs from patient PBC9 were cocultured for 12 d with APCs loaded with serial concentrations of rPDC-E2 protein (as indicated) mixed with either
human anti–PDC-E2 mAb, a control mAb, control ICs, or F(ab) 2 fragment of the human anti–PDC-E2 mAb. (C) PBMCs from patient PBC11 were
cocultured for 12 d with APCs loaded with serial concentrations of rPDC-E2 protein (as indicated) mixed with affinity purified autoAbs from PBC sera
or control Abs.120 CD8  Cells in PBC
specific CTLs in vivo are actively involved in the inflam-
matory responses and cytolytic destruction of BECs. The
PD5-specific CD8  T cells in the peripheral blood of pa-
tients cannot be detected directly with ex vivo intracellular
cytokine assay (data not shown), suggesting that the fre-
quency of the autoAg-specific CD8  T cells in circulation
is very low. Clearly, additional studies are needed using
PD5-bearing tetramer reagents and cell populations within
the lymph nodes and the liver to determine if the PD5-spe-
cific CD8  CTL are selectively homing to the liver.
PDC-E2–specific autoreactive CTLs appear primed in
vivo only in PBC patients. These data prompted us to hy-
pothesize that a previously described nonconventional
mechanism of Ag presentation, “cross-priming” or “cross-
presentation,” is involved in the maintenance and/or am-
plification of CTL response against PDC-E2, with PDC-
E2-specific autoAb playing a key role. Professional APCs
have been shown capable of intracellular processing of ex-
ogenous Ag using proteosomes to generate peptides pre-
sented by MHC class I (23, 24), the exogenous Ag being
presented by the same APCs to both CD4  and CD8  T
cells (25). This is important for the induction of immunity
to pathogens that avoid professional APCs (26). The pre-
cise nature of the APCs that are able to take up, process,
and present exogenous Ags in association with MHC class
I molecules remains to be defined. However, in vitro stud-
ies suggest that DCs (27–29), macrophages (30), or B cells
(31) might be involved. Cross-priming is generally ineffi-
cient, but the efficiency is much higher with macropi-
nocytosis (32) and phagocytosis of the particle (33, 34).
Phagocytosis of apoptotic cells also results in efficient
MHC class I–restricted Ag presentation in macrophages
and/or DCs (29, 35, 36). DCs in murine models have
been shown to mediate internalization of Ag–Ig complexes
(ICs), and promote efficient MHC class I as well as class
II–restricted Ag presentation (37). In terms of MHC class
II presentation, Fc Rs, which bind ICs represent a privi-
leged Ag internalization route for efficient MHC class II–
restricted Ag presentation in DCs (38). In murine systems,
it has been suggested that DCs are capable of taking up
ICs, and presenting the appropriate processed antigenic
peptide to CD4  T cells, which in turn activate DCs, and
convert them into DCs capable of priming CD8  T cells
in vivo (37).
In this study, a PDC-E2–specific CD8  CTL line has
been induced from PBMCs by stimulating them with solu-
ble Ag, suggesting the potential for cross-priming. Further,
rPDC-E2-ICs could be internalized, processed, and pre-
sented by APCs much more efficiently than soluble protein
alone in the induction of specific CTLs in vitro. PDC-E2-
ICs are present only in PBC patients in vivo because PDC-
E2–specific autoAbs are detected exclusively in PBC pa-
tients. In transgenic mice, cross-presentation can remove
autoreactive CD8  T cells and may tolerize the CD8 
compartment to self-Ags (27). Since the cross-presentation
pathway is involved in both cross-tolerance and cross-
priming, the mechanism by which Ags gain access to this
pathway is likely to affect both aspects. What determines
whether tolerance or immunity is induced is unclear, but
CD4  T cell help appears to be important (28, 39), which
is in accordance with the evidence that PDC-E2–specific
Th cell responses have been observed in most PBC pa-
tients. Another important factor might be the dose of Ag
presented (40). One additional explanation for the selective
induction of the PDC-E2–specific CTLs in PBC is that, in
addition to the role of autoAbs in forming ICs, autoreac-
tive B cells specific for PDC-E2 might play a role as APCs
in the generation of T cell–mediated immune responses. In
particular, activated B lymphocytes are highly efficient
APCs for the specific Ag that their surface Igs bind; B cells
are required as APCs to generate pathogenic autoimmune
T cell responses in NOD mice (41, 42).
IgA is transcytosed and can be transported into BECs. In
fact, PDC-E2 specific IgA has been detected in the bile of
PBC patients (43). We have shown previously that anti-
genic materials reactive with antimitochondrial Abs can be
detected in BECs of PBC patients but not in control indi-
viduals (44), suggesting that the autoAg PDC-E2 is either
expressed at a higher level or presented in a more antigenic
form in BECs of PBC patients. Both scenarios may render
this protein more accessible for binding with autoreactive
IgA inside the cells; endogenously synthesized PDC-E2
could be bound with autoAb in the cytosol, losing its capa-
bility to enter the mitochondria, resulting in the accumula-
tion within the cytosol, which in turn could lead to pro-
cessing via the MHC class I presentation pathway and
recognized by the PDC-E2 specific CD8  CTL. In fact,
intracellular neutralization of influenza virus by specific IgA
has been suggested using a Madine-Darby canine kidney
cell line (45). We have also shown the colocalization of
PDC-E2 with IgA from PBC patients within the same Ma-
din-Darby canine kidney cell line (46). Moreover, when
the cells die, the autoAb bound to the dominant B cell
epitope may cover the overlapping or adjacent CD4  and
CD8  epitopes, protecting them from degradation by pro-
teases, and the Ab-peptide complex may be internalized ef-
ficiently by APCs. Once being taken up by APCs, the
CD4  epitope or CD8  epitope on the peptide is revealed,
processed, and presented by MHC class I and class II mole-
cules, respectively. These peptides will then activate au-
toreactive CD4  and CD8  T cells to amplify the overall
level of autoimmunity, including expansion of autoreactive
effector T cells to mediate continued damage on BECs.
In previous studies, we identified both the major B cell
epitope as well as a class II–restricted T cell epitope for
PDC-E2. Interestingly, both epitopes were located within
the inner lipoyl domain with significant overlap (1, 47). It
is striking to find that the newly identified immunodomi-
nant MHC class I–restricted CD8  epitope, PD5 159–167,
overlaps with the B cell epitope, and partially overlaps with
the CD4  epitope 163–176. The overlapping of the im-
munodominant T cell and B cell epitopes has also been ob-
served in myelin basic protein (7, 48), the proteolipid pro-
tein in multiple sclerosis (49–52), and glutamic acid
decarboxylase 65 in insulin-dependent diabetes mellitus (8,
53, 54), suggesting that this is a common theme for au-121 Kita et al.
toimmune diseases. It is well recognized that B cells, CD4 
Th cells, and CD8  CTLs are functionally interrelated, as
indicated by the fact that CD4  Th cells provide important
support for both Ab response and for the generation and
maintenance of the CTL response. However, by conven-
tional mechanisms of Ag presentation there is no require-
ment for the target epitopes of these different subsets of
lymphocytes to be closely connected physically. Actually,
targets for CD4  cell and CD8  cells are usually generated
through different pathways and are not even derived from
the same polypeptide molecule. CD4  T cells recognize
epitopes that are derived from exogenous proteins taken up
by APCs and processed in the endocytic vesicles and are
presented by MHC class II. On the other hand, CD8  T
cells recognize epitopes that are derived from endoge-
nously synthesized proteins processed by proteosomes and
are presented by MHC class I. In this work and our previ-
ous study, we have examined the full-length PDC-E2 pro-
tein of 561 amino acid residues for the B cell, CD4  T cell,
and CD8  T cell epitopes in a systematic way. However,
the only epitope for each category we have identified is lo-
calized within a short segment of amino acid residues. Effi-
cient uptake of the PDC-E2 Ag coupled with specific au-
toAbs (ICs), and cross-presentation, if substantiated by
further studies, may explain the unusual clustering of B cell
and T cell epitopes on the autoAg and reveals a novel func-
tional association between the humoral and cellular arms of
autoimmunity. Although this mechanism does not address
the question of what factor(s) initiate the autoimmune cas-
cade that leads to the development of PBC, it may play an
important role in the amplification of autoimmunity and
progression of the disease.
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